Key Developments

On March 19, 2024, The Aesthetic Society, the leading authority on aesthetic plastic surgery, and The Aesthetic Foundation, the philanthropic research and education arm of The Aesthetic Society, announced the launch of the American Registry for Breast Implant Surveillance (ARISE), powered by their innovative Aesthetic One app. ARISE revolutionizes the landscape of breast implant registries by partnering with Aesthetic One, an FDA-recognized app dedicated to digital registration of breast implant devices used in aesthetic and reconstructive cases
On January 2, 2024, CollPlant Biotechnologies, a regenerative and aesthetics medicine company, announced its initiation of a pre-clinical trial to evaluate commercial-size, 3D-bioprinted, regenerative breast implants. Currently, there are no commercial products that allow regeneration of soft tissues such as the breast.
In February 2022, CELLINK, a BICO Group company and CollPlant Biotechnologies, a regenerative and aesthetic medicine company, announced a collaboration agreement. Under the terms of agreement, CELLINK's high-throughput, multi-material extrusion bioprinter will be explored for the development of large-scale production of CollPlant's 3D bioprinted regenerative breast implants,
In May 2021, GC Aesthetics, a medical technology company, announced the launch of its next generation of breast implants, PERLE. PERLE is a highly innovative line of smooth breast implants that features a proprietary surface technology (BioQ)